Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
about
A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonismInteractions of human melanocortin 4 receptor with nonpeptide and peptide agonistsInvestigation of the interaction between the atypical agonist c[YpwFG] and MOR.Modeling activated states of GPCRs: the rhodopsin template."Carba"-analogues of fentanyl are opioid receptor agonists.Action of molecular switches in GPCRs--theoretical and experimental studies.Homology modeling of opioid receptor-ligand complexes using experimental constraintsDevelopment and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsFunctional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor.Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffoldNeuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief.Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesModulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist propertiesMolecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism.Biological activity of sporolides A and B from Salinispora tropica: in silico target prediction using ligand-based pharmacophore mapping and in vitro activity validation on HIV-1 reverse transcriptase.The role of water and sodium ions in the activation of the μ-opioid receptor.Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.Molecular modeling study of the opioid receptor interactions with series of cyclic deltorphin analogues.Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.Tryptophan-Containing Non-Cationizable Opioid Peptides - a new chemotype with unusual structure and in vivo activity.Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity.The inverse type II β-turn on D-Trp-Phe, a pharmacophoric motif for MOR agonists.
P2860
Q24317131-E3D187F3-5986-4C16-8979-47801246FD51Q24653618-FE4ADB95-765C-4471-89C3-942E41A7934FQ31151838-15143549-8583-4240-86E2-63B557519E79Q33647180-70FFED8C-6BA5-4E2E-9BC7-3AA0A9415575Q33766279-7D7919E9-656A-4A94-A690-52470A83487EQ34251407-05DCEFF4-C0C3-4316-B170-AE58AF3A3F62Q34651393-80E8644E-CFCA-4189-9DC9-580EBE838407Q35621534-2581DEED-64A4-4D94-A485-69E7BE0A0DB5Q36635468-C5D27B70-86D0-4773-BD29-F82671C65AFAQ36947975-E12D8751-C23D-4A8F-B6B3-D1A7A670C275Q37319610-566890CE-A3FB-4E53-9783-ADE54511FE48Q37342753-E39C0498-5CB6-462C-9319-2F19A8E1CE38Q38217456-A5BE141C-33CF-4D7E-8B3C-81F6393B6EB2Q38297140-D24294D5-6947-44A5-B577-51D421E0658FQ39033568-25FB6F18-94FF-4D99-826B-2E4747954DD9Q39299621-AFA74ED0-294C-4164-AFA2-9089F3457B38Q39793785-9C29CBFA-F8E4-4209-8501-A625499A7A0EQ40293299-FF9B7D45-FC87-4AB0-A403-AD8107F36038Q42259388-34DD728E-3667-4C83-8FE7-7FA50CABC398Q44340498-313A41BE-C3C0-46CB-BDA9-55F98B742EA8Q44347928-C777F336-9072-4D4F-A908-66C884475CD6Q44350539-76C33ED0-8615-485A-AB7B-7F807330223AQ44350676-06C2899A-3FAD-47C5-A663-DCED4B5A8439Q44350759-9E161E26-EADC-473D-A09F-CEA66E7B623FQ47388982-78CD11F6-4B67-4D08-A5FC-66366A88CEC2Q51552311-1259DBDD-7478-4D7B-81B8-20A1CC59FAD9
P2860
Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Complex of an active mu-opioid ...... from experimental constraints.
@en
Complex of an active mu-opioid ...... from experimental constraints.
@nl
type
label
Complex of an active mu-opioid ...... from experimental constraints.
@en
Complex of an active mu-opioid ...... from experimental constraints.
@nl
prefLabel
Complex of an active mu-opioid ...... from experimental constraints.
@en
Complex of an active mu-opioid ...... from experimental constraints.
@nl
P2093
P356
P1433
P1476
Complex of an active mu-opioid ...... from experimental constraints.
@en
P2093
Andrei L Lomize
Carol B Fowler
Harry LeVine
Henry I Mosberg
Irina D Pogozheva
P304
15796-15810
P356
10.1021/BI048413Q
P407
P577
2004-12-01T00:00:00Z